MedPath

Almonertinib

Generic Name
Almonertinib
Drug Type
Small Molecule
Chemical Formula
C30H35N7O2
CAS Number
1899921-05-1
Unique Ingredient Identifier
T4RS462G19
Background

Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).

Indication

1.用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。

2.用于表皮生长因子受体（EGFR）敏感突变阳性局部晚期或转移性非小细胞肺癌（NSCLC）患者一线治疗。

Clinical Trials
Related News

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Phase 3
Recruiting
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
Radiation: SBRT
First Posted Date
2023-04-05
Last Posted Date
2023-04-05
Lead Sponsor
Shanghai Cancer Hospital, China
Target Recruit Count
300
Registration Number
NCT05800223
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Phase 3
Recruiting
Conditions
Brain Metastases
Radiotherapy
EGFR Activating Mutation
Interventions
Radiation: brain radiotherapy
First Posted Date
2023-03-14
Last Posted Date
2023-03-14
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
232
Registration Number
NCT05768490
Locations
🇨🇳

Sun-Yat-Sen university, Guangdong, Guangzhou, China

Almonertinib Plus Metronomic Oral Vinorelbine

Not yet recruiting
Conditions
EGFR
Third-generation TKI
NSCLC
Interventions
First Posted Date
2022-12-23
Last Posted Date
2022-12-23
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
40
Registration Number
NCT05663177

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Phase 2
Recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2022-12-23
Last Posted Date
2022-12-23
Lead Sponsor
West China Hospital
Target Recruit Count
55
Registration Number
NCT05662813
Locations
🇨🇳

West China Hospital，Sichuan University, Chendu, Sichuan, China

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Phase 2
Not yet recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2022-09-09
Last Posted Date
2022-09-14
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
38
Registration Number
NCT05534113

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Phase 1
Not yet recruiting
Conditions
Relapsed or Advanced Non-small Cell Lung Cancer
Interventions
First Posted Date
2022-08-17
Last Posted Date
2022-08-17
Lead Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Target Recruit Count
160
Registration Number
NCT05503888

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Phase 2
Conditions
NSCLC, Stage III
Interventions
First Posted Date
2021-07-07
Last Posted Date
2021-07-07
Lead Sponsor
Yuan Chen
Target Recruit Count
26
Registration Number
NCT04952168
Locations
🇨🇳

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Phase 3
Not yet recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: chemotherapy
First Posted Date
2021-07-07
Last Posted Date
2021-07-07
Lead Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Target Recruit Count
220
Registration Number
NCT04951648
Locations
🇨🇳

Sun yat-sen Univerisity Cancer Center, Guangzhou, Guangdong, China

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Phase 3
Recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2021-07-07
Last Posted Date
2022-06-16
Lead Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Target Recruit Count
150
Registration Number
NCT04951635
Locations
🇨🇳

Shandong Cancer Hospital, Ji'nan, Shandong, China

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Not Applicable
Not yet recruiting
Conditions
EGFR Activating Mutation
NSCLC
Leptomeningeal Metastasis
Interventions
First Posted Date
2021-06-29
Last Posted Date
2021-06-29
Lead Sponsor
Second Affiliated Hospital of Nanchang University
Target Recruit Count
69
Registration Number
NCT04944069
Locations
🇨🇳

The Second Afiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy